Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer

Malignant Neoplasm of Thyroid Stage I Clinical Trial

Status Completed

Clinical Trial Summary

Differentiated thyroid cancer is the most common neoplasm of endocrine system. After surgery and radioiodine treatment, thyroid stimulating hormone (TSH) suppression is the main goal which is achieved with levothyroxine treatment. Levothyroxine causes increased thyroid hormones which can have negative impact on bone and cardiovascular system. Anecdotal reports have shown that metformin can induce TSH suppression without change in T3 and T4 concentration. The purpose of this study was to prescribe metformin as additional drug to levothyroxin in order to decrease levothyroxine dosage.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Malignant Neoplasm of Thyroid Stage I
• Malignant Neoplasm of Thyroid Stage II
• Neoplasms
• Thyroid Diseases
• Thyroid Neoplasms

• NCT number: NCT01341886
• Study type: Interventional
• Source: Mashhad University of Medical Sciences
• Status: Completed
• Phase: N/A
• Start date: April 2010
• Completion date: April 2011